As part of its broader strategy to secure a firm and competitive footing in the $232 billion personalized medicine market, Rainbow Coral Corp. has identified Canada as a potentially lucrative market for opportunities and partnerships that could lead to profitable new medical technologies and innovations.
"In spite of its world-class healthcare system, Canada remains a highly underdeveloped market for personalized medicine products, services and innovations," RBCC CEO Patrick Brown stated in the press release. "Our research indicates that some forward-thinking investment there could lead to big returns for our company as we work to deliver new cutting-edge tools for the future of global medicine."
RBCC is already executing an aggressive strategy for market penetration in the United States. The company recently signed a joint venture agreement with TheraKine Ltd., the developer of a revolutionary, sustained-release drug delivery platform designed to make the local delivery of biologic agents and small molecules safer, more effective, and more convenient.
In addition, RBCC's joint-venture partner, Nano3D BioSciences, has entered into a distribution agreement with St. Louis-based scientific products distributor MIDSCI to sell its revolutionary BioAssembler product line in the multi-billion-dollar U.S biotechnology market.
"It's a wide-open market with unlimited potential for growth," Brown said.
For more information visit www.RainbowBioSciences.com
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net